Back to top

Tale of the Tape

Although Merrimack Pharmaceuticals Inc. (MACK) is up over 26.5% in the past four weeks, investors may be concerned. After all, MACK is now in overbought territory, at least when looking at its RSI value of 84.5. If that wasn’t enough, investors should also note that Merrimack Pharmaceuticals Inc. possesses a Zacks Rank #4 (Sell), so if analyst perception is any guide, we could witness a slump in MACK shares before too long.